8-K: Shattuck Labs Prices $4.00 Common Stock Offering

Shattuck Labs, Inc. announced the pricing of its underwritten public offering of common stock and pre-funded warrants, raising capital through the sale of over 18 million shares and warrants.

Summary

• Shattuck Labs, Inc. has completed an underwritten public offering of its common stock and pre-funded warrants.
• The offering included 10,879,376 shares of common stock at $4.00 per share and 7,870,624 pre-funded warrants at $3.9999 per share.
• The company also granted underwriters an option to purchase an additional 2,812,500 shares, which was fully exercised.
• The offering was made under a shelf registration statement filed on January 13, 2026, and declared effective on January 21, 2026.
• The offering is expected to close on June 11, 2026.
• Pre-funded warrants are exercisable immediately and are subject to beneficial ownership limitations, which can be adjusted with prior notice.
• The underwriting agreement includes customary representations, warranties, and indemnification obligations.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it successfully raises capital but also introduces potential dilution for existing shareholders.

Positives

• Successful capital raise through a public offering of common stock and pre-funded warrants.
• Full exercise of the underwriters' option to purchase additional shares, indicating strong demand.
• The offering was conducted under an effective shelf registration statement, streamlining the process.
• Pre-funded warrants provide immediate exercisability for investors.

Negatives

• The offering dilutes existing shareholders' ownership.
• The exercise of warrants and pre-funded warrants could lead to further dilution in the future.

Risks

• Beneficial ownership limitations on pre-funded warrants could restrict investor participation or future actions.
• The underwriting agreement contains customary representations and warranties, which if breached, could lead to liabilities.
• Future sales of common stock by the company or existing shareholders could negatively impact the stock price.

Future Outlook

The offering is expected to close on June 11, 2026. The pre-funded warrants are exercisable at any time after issuance, subject to beneficial ownership limitations.

Industry Context

StockSavvy.ai notes that capital raises through equity offerings are common for biotechnology and pharmaceutical companies like Shattuck Labs to fund ongoing research, development, and clinical trials. The use of pre-funded warrants can be an attractive mechanism for investors seeking to avoid immediate ownership thresholds while securing a position in the company.

Stakeholder Impact

• Shareholders: Potential dilution of ownership and voting power due to the issuance of new shares and exercisable warrants.
• Investors: Opportunity to invest in Shattuck Labs through common stock or pre-funded warrants, with flexibility in ownership thresholds.
• Underwriters: Earned fees and commissions from the offering.

Next Steps

• Closing of the offering on June 11, 2026.
• Potential future exercise of pre-funded warrants by holders.

Key Dates

Recommendation

The filing details a capital raise which is a standard event for companies in this sector. While it provides necessary funding, it also introduces dilution. A 'hold' recommendation is appropriate pending further analysis of how the raised capital will be deployed and its impact on future growth and profitability.

Keywords

Shattuck Labs, Public Offering, Common Stock, Pre-funded Warrants, Underwriting Agreement, SEC Filing, Form 8-K, Capital Raise